T-cell-directed therapies in inflammatory bowel diseases

Giovanni Monteleone, Flavio Caprioli

Research output: Contribution to journalArticlepeer-review


Gut inflammation occurring in patients with IBDs (inflammatory bowel diseases) is associated with exaggerated and poorly controlled T-cell-mediated immune responses, which are directed against normal components of the gut flora. T-cells accumulate in the inflamed gut of IBD patients as a result of multiple mechanisms, including enhanced recruitment of cells from the bloodstream, sustained cell cycling and diminished susceptibility of cells to undergo apoptosis. Activated T-cells produce huge amounts of cytokines, which contribute to amplify and sustain the ongoing mucosal inflammation. Strategies aimed at interfering with T-cell accumulation and/or function in the gut have been employed with clinical success in patients with IBDs. In the present article, we review the available results showing that T-cell-directed therapies are useful to dampen the tissue-damaging immune response in IBDs.

Original languageEnglish
Pages (from-to)707-715
Number of pages9
JournalClinical Science
Issue number12
Publication statusPublished - Jun 2010


  • Crohn's disease
  • Cytokine
  • Inflammatory bowel disease (IBD)
  • Interleukin
  • T-cell
  • Tumour necrosis factor (TNF)
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'T-cell-directed therapies in inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this